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Genetic defects in the adenosine deaminase (ADA) gene are among the most common
causes for severe combined immunodeficiency (SCID). ADA-SCID patients suffer from
lymphopenia, severely impaired cellular and humoral immunity, failure to thrive, and recur-
rent infections. Currently available therapeutic options for this otherwise fatal disorder
include bone marrow transplantation (BMT), enzyme replacement therapy with bovine
ADA (PEG-ADA), or hematopoietic stem cell gene therapy (HSC-GT). Although varying
degrees of immune reconstitution can be achieved by these treatments, breakdown of
tolerance is a major concern in ADA-SCID. Immune dysregulation such as autoimmune
hypothyroidism, diabetes mellitus, hemolytic anemia, and immune thrombocytopenia are
frequently observed in milder forms of the disease. However, several reports document
similar complications also in patients on long-term PEG-ADA and after BMT or GT treat-
ment. A skewed repertoire and decreased immune functions have been implicated in
autoimmunity observed in certain B-cell and/or T-cell immunodeficiencies, but it remains
unclear to what extent specific mechanisms of tolerance are affected in ADA deficiency.
Herein we provide an overview about ADA-SCID and the autoimmune manifestations
reported in these patients before and after treatment. We also assess the value of the
ADA-deficient mouse model as a useful tool to study both immune and metabolic dis-
ease mechanisms. With focus on regulatory T- and B-cells we discuss the lymphocyte
subpopulations particularly prone to contribute to the loss of self-tolerance and onset of
autoimmunity in ADA deficiency. Moreover we address which aspects of immune dysregu-
lation are specifically related to alterations in purine metabolism caused by the lack of ADA
and the subsequent accumulation of metabolites with immunomodulatory properties.
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THE ADA METABOLISM
THE ADA ENZYME
As an enzyme of the purine salvage pathway, adenosine deam-
inase (ADA) catalyzes the deamination of adenosine and 2′-
deoxyadenosine, as well as several naturally occurring methylated
adenosine compounds (Hirschhorn and Ratech, 1980; Ratech
et al., 1989). The deamination of adenosine and 2′-deoxyadenosine
gives rise to inosine and deoxyinosine, respectively (Hirschhorn
and Candotti, 2006). Further conversion of these deaminated
nucleosides leads to hypoxanthine, which can be either trans-
formed irreversibly into uric acid or salvaged into mononucle-
osides (Figure 1).
Although ADA is present in all cell types, its enzyme activ-
ity differs considerably among tissues. The highest amounts in
humans are found in lymphoid tissues, particularly the thymus,
Abbreviations: ADA, adenosine deaminase; Adora, adenosine receptor(s); ANA,
anti-nuclear antibody; BCR, B cell receptor; BMT, bone marrow transplanta-
tion; HLA, human leukocyte antigen; HSC, hematopoietic stem cell; HSC-GT,
hematopoietic stem cell gene therapy; PEG-ADA, pegylated bovine ADA; SCID,
severe combined immunodeficiency; TCR, T-cell receptor; TLR, Toll-like receptor;
Tregs, naturally occurring regulatory T cells.
the brain, and gastrointestinal tract. The ADA enzyme is ubiqui-
tously expressed both intracellularly and on the cell surface where
it complexes with two molecules of CD26 as a combined protein
(Kameoka et al., 1993).
THE ADA SUBSTRATES ADENOSINE AND 2′-DEOXYADENOSINE
2′-Deoxyadenosine is a component of DNA and primarily derives
from its breakdown. Therefore, 2′-deoxyadenosine concentration
is expected to be highest at sites of cell death, such as the bone
marrow and thymus, where lymphocytes undergo apoptotic death
during differentiation and selection. 2′-Deoxyadenosine behaves
as a cytotoxic metabolite and is generally considered the pri-
mary cause of lymphotoxicity in ADA-severe combined immun-
odeficiency (SCID; Hirschhorn and Candotti, 2006). The most
striking metabolic alteration in ADA deficiency is the accumu-
lation of massive amounts of dATP in erythrocytes and lym-
phocytes (Hirschhorn et al., 1992). This results from uptake
of increasing 2′-deoxyadenosine present in surrounding body
fluids with subsequent intracellular phosphorylation and trap-
ping.
Adenosine on the other hand is a component of adenine
nucleotides including ATP and RNA (Hirschhorn and Candotti,
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FIGURE 1 |The adenosine deaminase (ADA) metabolism. ADA is
an enzyme of the purine salvage pathway, which catalyzes the
irreversible deamination of adenosine and 2′-deoxyadenosine into
inosine and 2′-deoxyinosine, respectively. Most adenosine derives
from endogenous breakdown of ATP and degradation of RNA, or is
taken up exogenously by ubiquitously expressed nucleoside
transporters. Unlike adenosine, 2′-deoxyadenosine is formed by DNA
degradation is predominantly catabolized by ADA. Further conversion
of inosine nucleoside leads to hypoxanthine, which can either enter a
non-reversible pathway to uric acid or salvaged back into other
mononucleosides. In the absence of ADA, the presence of these
alternative “bypass” pathways results in normal concentrations of the
catabolic products of the enzyme reaction in patients with ADA-SCID.
Conversely, the levels of ADA substrates, adenosine and
2′-deoxyadenosine, are not only found in increased amounts in
extracellular body fluids, but they also “spill over” into additional
pathways normally only minimally utilized, thus contributing to the
pathogenic mechanisms of the disease.
2006). Elevated adenosine levels, as occurring in ADA deficiency
contribute to apoptosis and block in the differentiation of thy-
mocytes, causing severe T lymphopenia in mice and humans
(Apasov et al., 2001; Gaspar et al., 2009; Poliani et al., 2009). More-
over adenosine, acting through cell surface G protein-coupled
receptors, functions as an extracellular signal transducer in a
variety of physiological processes (Olah and Stiles, 1995). Apart
from T-cell receptor signaling (Huang et al., 1997), adenosine
is involved in the control of heart rate and blood pressure
(Fukunaga et al., 1982; Belardinelli et al., 1989), renal function
(Churchill and Bidani, 1982), inflammatory responses (Black-
burn,2003),and in neurotransmission (Fredholm and Dunwiddie,
1988).
ADA-SCID
Adenosine deaminase deficiency is the second-most prevalent
form (approximately 20%) of SCID. The overall incidence in
Europe is estimated to range between 1:375,000 and 1:660,000 live
births. ADA-deficient patients suffer from lymphopenia, severely
impaired cellular and humoral immune function, failure to thrive,
and a rapidly fatal course due to infection (Hirschhorn and
Candotti, 2006). Moreover, autoimmune manifestations are com-
monly observed in milder forms of the disease. Currently available
therapeutic options include bone marrow transplantation (BMT),
enzyme replacement therapy with bovine ADA (PEG-ADA), or
hematopoietic stem cell gene therapy (HSC-GT).
IMMUNE DEFECTS
Lymphopenia and attrition of immune function over time are the
two findings common to all presentations of ADA deficiency. It
is associated with thymic hypoplasia and a severe depletion of
all three major categories of lymphocytes, T-, B-, and NK-cells
(Buckley et al., 1997). Absence of cellular and humoral immu-
nity and a rapidly fatal course due to infections with fungal, viral,
and opportunistic agents are characteristic of early onset forms
of ADA deficiency (Giblett et al., 1972; Buckley et al., 1997).
Total immunoglobulin levels may be only slightly depressed at
birth due to the maternal contribution of IgG, whereas both
IgM and IgA, which ordinarily do not cross the placental bar-
rier, are often absent. However, once IgG levels decline as maternal
antibodies are cleared, a pronounced hypogammaglobulinemia
signals the absence of humoral immunity (Morgan et al., 1987;
Hirschhorn and Candotti, 2006). About 20% of ADA-SCID cases
occur later in childhood (delayed) or beyond (late/adult onset).
Delayed or late-onset patients have significant immunodeficiency,
but variable clinical manifestations (Ozsahin et al., 1997). These
forms show progressive immunological and clinical deteriora-
tion, often associated with autoimmune manifestations, includ-
ing hemolytic anemia, and immune thrombocytopenia (Parkman
et al., 1975; Aiuti et al., 2003). Serum immunoglobulin levels
are altered in late-onset patients, with IgG2 levels being highly
reduced or absent. IgE levels are elevated and often associated to
eczema and asthma. An inability to produce antibodies against
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polysaccharide and pneumococcal antigens was frequently found
in ADA-SCID patients with milder forms of the disease (Levy et al.,
1988).
NON-IMMUNE DEFECTS
The initial and most devastating presentation of ADA-SCID is
due to the immune defects (Gaspar et al., 2009). Nonetheless,
several non-immune abnormalities have been described in ADA
deficiency, indicating that this disease should be considered a
systemic metabolic disorder (Aiuti et al., 2003; Hirschhorn and
Candotti, 2006). ADA is ubiquitously expressed in all cell types;
when absent, the systemic metabolic toxicity is frequently asso-
ciated with organ damage (Sauer and Aiuti, 2009). These include
hepatic and renal disease (Bollinger et al., 1996), skeletal alterations
(Sauer et al., 2009), neurological abnormalities (Honig et al., 2007;
Titman et al., 2008), and behavioral impairments (Rogers et al.,
2001). Because complications from infections usually predomi-
nate in the clinical presentation of infants with ADA deficiency,
the full spectrum of non-immunologic manifestations and their
natural course may be obscured (Honig et al., 2007). It is impor-
tant to note, that several abnormalities have been described in few
patients only, and might reflect effects of infectious agents rather
than primary defects due to ADA deficiency: i.e., renal and adrenal
abnormalities, phyloric stenosis, and hepatic disease (Hirschhorn
and Candotti, 2006).
THERAPIES FOR ADA DEFICIENCY
Bone marrow transplantation with allogeneic HSC has long been
considered the mainstay of ADA-SCID treatment. However, unlike
other SCID forms, two other treatment options are available for
ADA-SCID: enzyme replacement therapy with pegylated bovine
ADA (PEG-ADA) and autologous HSC-GT (Hershfield et al., 1987;
Aiuti et al., 2009). The availability of different treatment modal-
ities presents an opportunity for improved patient care but also
difficulties in deciding upon the specific choice of treatment for
individual patients (Figure 2). Making the correct choice is fur-
ther complicated by the fact that ADA deficiency is not purely an
immune defect, and that the systemic manifestations, which can
be of major clinical consequence, must also be managed (Gaspar
et al., 2009).
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hematopoietic stem cell-transplantation (BMT) from allogeneic
human leukocyte antigen (HLA)-compatible sibling donors
resulting in long-term survival and effective immune reconsti-
tution is the treatment of choice for patients with ADA-SCID and
other severe variants of primary immunodeficiencies. Since less
than 20% of ADA-SCID patients have access to HLA-matched
family donors, transplants are often performed from mismatched
family or matched unrelated donors (Antoine et al., 2003; Gaspar
et al., 2009; Ferrua et al., 2010). A recent retrospective analysis
on the specific outcome of transplants for ADA-SCID collected
data from several multicenter studies and analyzed the survival
of 106 patients who received a total of 119 transplants (Hassan
et al., 2012). BMT from matched sibling and family donors had
a significantly better overall survival (86 and 81%) in compari-
son to BMT from matched unrelated (66%) and haploidentical
donors (43%). Indicating that despite recent progress in trans-
plantation, the use of alternative donors is still associated with
a reduced overall survival (Gaspar et al., 2009). This is further
complicated by the fact that ADA-SCID patients are more difficult
to transplant especially from unrelated and haploidentical donors
possibly due to their need for conditioning and the underlying
metabolic nature of the disease (Gaspar et al., 2009; Sauer et al.,
2009). While superior survival was seen in patients who received
unconditioned transplants in comparison to myeloablative proce-
dures (81 and 54%), non-engraftment was a major problem after
unconditioned haploidentical transplants (Hassan et al., 2012).
Long-term immune recovery showed that regardless of trans-
plant type, overall T-cell numbers were similar although a faster
rate of T-cell recovery was observed following matched sibling
or matched unrelated BMT. Humoral immunity and donor B
cell engraftment was achieved in nearly all evaluable surviving
patients and most patients were able to discontinue immunoglob-
ulin replacement, suggesting that immune recovery is relatively
complete (Hassan et al., 2012). According to the available data,
the immunological and metabolic recovery after transplant is well
maintained even after 10 years or longer in some patients (Gaspar
et al., 2009).
Nevertheless delayed or suboptimal immune reconstitution as
a result of poor early engraftment or gradual decline in immune
functions is observed in a significant fraction of surviving patients
(Gaspar et al., 2009). Complications such as graft-versus-host dis-
ease, autoimmune and inflammatory manifestations, persistent
infections, and disease-related issues have been described (Honig
et al., 2007; Titman et al., 2008; Mazzolari et al., 2009).
In summary, the results obtained with transplantation from
HLA-identical siblings or family donors indicate superior
donor/host compatibility and outcome both in terms of survival
and sustained immune recovery. Whereas the current evidence
suggests that haploidentical donor transplants (performed with or
without conditioning) have a poor chance of success and are there-
fore only undertaken if no other treatment options are available
(Gaspar et al., 2009).
ENZYME REPLACEMENT THERAPY WITH PEG-ADA
Enzyme replacement therapy with PEG-ADA was developed as
lifesaving, not curative treatment for patients lacking an HLA-
compatible donor. Attachment of PEG through lysine residues
confers several therapeutically beneficial properties to ADA (Abu-
chowski et al., 1977; Davis et al., 1981). This chemical modification
of the bovine enzyme reduces its immunogenicity and prevents its
degradation by plasmatic proteases as well as the binding of neu-
tralizing antibodies (Abuchowski et al., 1977; Davis et al., 1981).
Thereby the circulating life of the compound is prolonged from
minutes to days as clearance from the circulation is inhibited
(Booth and Gaspar,2009). Cellular uptake of PEG-ADA is insignif-
icant and its distribution is limited to the plasma. Enzymatically
active ADA continuously circulates and eliminates accumulating
adenosine and 2′-deoxyadenosine metabolites (Chan et al., 2005).
The principle of exogenous PEG-ADA administration is based
on the direct conversion of accumulating ADA substrates in the
plasma and the indirect reduction of intracellular toxic metabolites
by diffusion.
www.frontiersin.org August 2012 | Volume 3 | Article 265 | 3
Sauer et al. Autoimmunity in ADA-SCID
FIGURE 2 | Current therapeutic options in ADA-SCID and reported
autoimmune manifestations after treatment. Immune reconstitution
in ADA deficiency can be achieved by bone marrow transplantation,
enzyme replacement, or gene therapy, nonetheless recovery of immune
functions may vary depending on the applied treatment and patient’s
characteristics. Treatment of choice remains bone marrow
transplantation from an HLA-identical sibling donor, while transplants
from alternative donors are associated with high morbidity and mortality.
Enzyme replacement therapy using pegylated bovine ADA is a
non-curative treatment requiring weekly intramuscular injections with
PEG-ADA. ADA-SCID has been the pioneer disease for the development
of human gene therapy. It is based on the reinfusion of autologous HSC
transduced with a retroviral vector containing the ADA cDNA. Variable
degrees of immune reconstitution can be achieved by these treatments,
but onset of autoimmunity is of concern in post-treatment ADA-SCID
patients. Reported autoimmune manifestations include: autoimmune
hypothyroidism, diabetes mellitus, thrombocytopenia, hemolytic anemia,
and development of anti-ADA antibodies. HLA, human leukocyte antigen;
BMT, bone marrow transplantation; MUD, matched unrelated donor;
PEG-ADA, pegylated bovine ADA; HSC, hematopoietic stem cell; PSC,
pluripotent stem cell; CLP, committed lymphocyte precursor; NK, natural
killer cell.
To date more than 150 patients worldwide have received this
treatment (Booth and Gaspar, 2009; Gaspar et al., 2009). PEG-
ADA is usually administered weekly or bi-weekly by intramuscular
injections throughout life. In general, PEG-ADA treatment seems
to be well tolerated, with clinical benefits appreciable after the first
month of therapy (Figure 3). Studies have shown that upon the
initiation of PEG-ADA therapy, the absolute numbers of circulat-
ing T- and B-lymphocytes and NK-cells increase and protective
immune function develops (Weinberg et al., 1993). Although only
limited information is available, some analysis indicated that about
half of PEG-ADA treated patients discontinued IVIg (Gaspar
et al., 2009), whereas long-term follow-up suggests that immune
recovery is often incomplete (Booth and Gaspar, 2009). Two
retrospective studies showed that despite initial improvements, the
lymphocyte counts of all PEG-ADA treated patients were below the
normal range at all times. A gradual decline of mitogenic prolifer-
ative responses occurred after a few years of treatment and normal
antigenic responses occurred less than expected (Kohn, 2008;
Serana et al., 2010). No toxic or hypersensitivity reactions have
been reported with PEG-ADA administration. However, several
other side effects have been reported including manifestations of
immune dysregulations including autoimmunity (type I diabetes,
hypothyroidism, immune thrombocytopenia, hemolytic anemia)
and allergic manifestations (Notarangelo et al., 1992; Ozsahin
et al., 1997). An additional concern with PEG-ADA beyond about
8–10 years is the emergence of serious complications, including
lymphoid and hepatic malignancies, and progression of chronic
pulmonary insufficiency (Gaspar et al., 2009).
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FIGURE 3 | Immune reconstitution and development of
autoimmunity after PEG-ADA treatment. Enzyme replacement therapy
with pegylated bovine ADA is a lifesaving but non-curative treatment for
ADA-SCID patients. It provides metabolic detoxification and protective
immune function with patients remaining clinically well, but immune
reconstitution is often suboptimal and may not be long-lived. Shortly after
initiation of PEG-ADA treatment, patients show recovery of B-cell counts,
followed by a gradual increase in T-cell numbers and reconstitution of
immune cell functions. However, the long-term consequences of
PEG-ADA treatment are unknown. Immune recovery in B and T- cells is
below normal levels. Major concerns are the susceptibility to
opportunistic infections and the development of autoimmunity due to
lymphopenia with gradual decline of immune functions and perturbation
of T- and B-cell tolerance.
The main side effect associated with the use of PEG-ADA
is the development of anti-ADA antibody. The development of
specific IgG antibody to bovine peptide epitopes of PEG-ADA
has been reported by several groups and often coincides with an
improvement in humoral immunity (Chaffee et al., 1992; Lainka
et al., 2005; Booth et al., 2007). In about 10% of treated patients,
inhibitory antibodies lead to the enhanced clearance of PEG-ADA
with subsequent decline in metabolic parameters and immune
function (Chaffee et al., 1992; Hershfield, 1995; Lainka et al., 2005).
GENE THERAPY
Hematopoietic stem cell gene therapy is a promising therapeutic
option for genetic disorders of the immune system (Bordignon
and Roncarolo, 2002; Fischer et al., 2005). ADA-deficient SCID
has been under intensive preclinical and clinical investigation and
nowadays represents a paradigmatic model of gene therapy for
inherited disorders (Aiuti et al., 2003, 2007). The strong rationale
for somatic gene therapy and the need for alternative treatments
led to the design of clinical trials based on retroviral-mediated gene
transfer of the normal ADA gene into autologous HSCs (Aiuti,
2004). Replication-deficient, recombinant retroviruses derived
from the backbone of Moloney murine leukemia virus (MLV)
were selected for these trials because of the available long-term
experience and their ability to efficiently insert the therapeutic
gene into the genome of dividing hematopoietic cells.
Since 2000, 37 patients have been treated in Italy, UK, and USA,
achieving substantial clinical benefit in the majority of them. All
patients received reduced intensity conditioning and PEG-ADA
was discontinued to exploit the selective growth advantage for
gene corrected over defective cells. At present, all patients are
alive and in 26 patients PEG-ADA is no longer required (Aiuti
et al., 2009; Gaspar et al., 2011; Montiel-Equihua et al., 2012).
Gene therapy resulted in sustained engraftment of transduced
cells, increased lymphocyte counts, improvement of cellular and
humoral responses, and effective metabolic detoxification (Aiuti
et al., 2009; Gaspar et al., 2011). Gene corrected cells were detected
in myeloid and lymphoid subsets, the latter being more repre-
sented due to their survival advantage (Aiuti et al., 2009; Gaspar
et al., 2011). In the HSR-TIGET study, all children maintained
stable engraftment of vector ADA-transduced CD34+ cells with
sustained systemic detoxification (Aiuti et al., 2009). At present, 15
of the 18 treated children do not require enzyme replacement ther-
apy, with the longest follow-up at 11 years after treatment (Aiuti
et al., 2009; Ferrua et al., 2010). These findings demonstrated the
clinical efficacy of ADA gene transfer in restoring normal immune
function and metabolic functions of ADA-SCID patients.
Unlike trials with gammaretroviral vectors in other diseases like
X-linked SCID (Hacein-Bey-Abina et al., 2008; Howe et al., 2008),
chronic granulomatous disease (Ott et al., 2006) and Wiskott–
Aldrich Syndrome (Trobridge, 2011), the cumulative experience
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of these studies for ADA-SCID (Aiuti et al., 2009; Ferrua et al.,
2010; Montiel-Equihua et al., 2012) did not reveal leukemic or
oncogenic events, indicating that ADA-SCID gene therapy has a
favorable risk/benefit profile. Unique risk factors may have con-
tributed to the differential outcome of the other trials, such as
vector constructs or promoters, inappropriate expression of trans-
genes involved in cell signaling (Kohn, 2008), cooperation between
transgene and cellular oncogenes (Dave et al., 2009), or the disease
background itself (Shou et al., 2006).
AUTOIMMUNITY IN ADA-SCID
Immunodeficiency and autoimmune phenomena may occur con-
comitantly in the same individual (Etzioni, 2003). Immune dysreg-
ulation, which often manifests as multiple forms of autoimmunity,
can affect both the adaptive and innate immune system, indicating
that all these immune components are required for the appropri-
ate development of tolerance in humans (Cunningham-Rundles,
2011). Since varying degrees of immune reconstitution can be
achieved by the available treatment options for ADA-SCID, break-
down of tolerance and development of autoimmunity can repre-
sent a major concern. Autoimmune dysregulation are frequently
observed in patients with milder forms of the disease or late-onset
patients. They may manifest as autoimmune hypothyroidism, dia-
betes mellitus, hemolytic anemia, and immune thrombocytopenia
(Notarangelo et al., 1992; Ozsahin et al., 1997; Figure 2).
Similar complications, such as autoimmune hemolytic anemia
and autoimmune thyroiditis, have also been reported in at least
nine patients after long-term PEG-ADA treatment (Ratech et al.,
1989; Notarangelo et al., 1992; Ozsahin et al., 1997; Gaspar et al.,
2009; Serana et al., 2010). Refractory hemolytic anemia was fatal in
three patients (Gaspar et al., 2009). Two additional studies assessed
defects in the lymphoid compartments of ADA-SCID patients fol-
lowing PEG-ADA. Different degrees of abnormalities in the B-cell
compartment and inability to respond to vaccines, despite the
presence of normal serum-Ig or hypogammaglobulinemia were
reported (Malacarne et al., 2005). Moreover, a retrospective lon-
gitudinal analysis in ADA-SCID patients treated with PEG-ADA
showed that decreased levels of newly produced B cells underlie
the progressive and significant decrease in circulating B cells in
these patients (Serana et al., 2010). Since long-term PEG-ADA
treatment is associated with abnormalities in B cell subsets, but
often also with a decrease in T-cell functions (Malacarne et al.,
2005), a limited B or T-cell repertoire combined with alterations
in peripheral tolerance could further favor breakdown of tolerance
(Figure 3).
No specific reports on immune dysregulation or autoimmu-
nity in BMT-treated ADA-SCID patients are available in liter-
ature (Serana et al., 2010). Nevertheless, autoimmune manifes-
tations have been reported in larger single-center studies on
BMT-treated patients with various kinds of immunodeficiencies,
including ADA deficiency (Mazzolari et al., 2009; Neven et al.,
2009). The major immune dysregulations observed in both studies
included thyroid autoimmunity, autoimmune hemolytic anemia,
and glomerulonephritis (Mazzolari et al., 2009; Neven et al., 2009).
Most recently autoimmune manifestations have also been
described in patients treated with HSC-GT (Aiuti et al., 2009).
Four ADA-SCID patients, including one patient that already
showed immune dysregulation while on PEG-ADA, developed
signs of autoimmunity, such as hemolytic anemia, thrombo-
cytopenia, autoimmune hepatitis, and autoimmune thyroiditis
(Aiuti et al., 2009 and unpublished observation).
ADA-DEFICIENT MOUSE MODEL
The availability of a genetic animal model for ADA deficiency
allowed a wide range of biochemical and immunological exper-
iments that are not feasible in humans. The first attempts to
generate ADA-deficient mice lead to their perinatal death due to
severe liver damage (Blackburn et al., 1998). Subsequent studies
suggested that ADA expression in trophoblast cells of the placenta
is critical for fetal development in the mouse. Thus, ADA-deficient
mice were successfully generated by specifically targeting expres-
sion of an ADA minigene to the trophoblast lineage of ADA+/−
mice and by inter-crossing these mice. This gave rise to litters that
contained mice expressing the ADA minigene in their placenta
that were also homozygous for the ADA null allele (ADA−/−;
Blackburn et al., 1998).
UNTREATED ADA−/−MICE
The ADA−/− mouse reproduces not only the biochemical but
also the immunological abnormalities of the human disease phe-
notype. They manifest both combined immunodeficiency as well
as metabolic abnormalities and are therefore commonly used to
assess the effect of ADA deficiency not only on the lymphoid
organs and peripheral blood, but also its systemic organ toxic-
ity. ADA−/− deficient mice die at approximately 3 weeks of age
from severe respiratory distress (Blackburn et al., 1998).
Initial examinations of the thymus and spleen revealed a sub-
stantial decrease in organ size. The cellular proportion from the
thymus of ADA−/−mice showed a significant increase in the per-
centage double-negative immature thymocytes, accompanied by
a decrease in the percentage of CD4+ or CD8+ single-positive
thymocytes. T-cell apoptosis was abundant in the ADA-deficient
thymi (Blackburn et al., 1998). ADA−/− splenic B lymphocytes
showed defects in proliferation and activation with high propen-
sity to undergo B cell receptor-mediated apoptosis. As a result,
profound loss of germinal center architecture was noted, which
may be responsible for impaired B cell development (Aldrich et al.,
2003). Lymphopenia was also seen in the peripheral circulation,
confirming that this model of ADA deficiency exhibits a SCID
phenotype.
At death, the severe immune deficiency and organ alterations
are the most prominent features, whereas no apparent autoim-
mune manifestations can be observed. The almost complete
absence of effector T- and B-cell populations in these mice and
the high levels of anti-inflammatory adenosine might prevent their
development in the first 3 weeks of life. Reconstitution of effector
T- and B-cells as well as metabolic detoxification after treatment
might therefore be requirements for the onset of autoimmunity
(Sauer et al., 2012a).
MODEL FOR AUTOIMMUNITY IN ADA-DEFICIENT MICE
Similarly to ADA-SCID patients, ADA−/− mice can be treated
with PEG-ADA, HSC-GT with transduced BM ADA−/− cells, or
BMT with wild type donor cells (Mortellaro et al., 2006; Sauer
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et al., 2009). A dose of 1000 U/kg/week of PEG-ADA starting from
postnatal day 10 provides rescue and metabolic detoxification in
ADA−/− mice (Blackburn et al., 2000). HSC-GT is performed
using a SIN-lentiviral vector driving ADA expression from the
phosphoglycerate kinase (PGK) promoter (Mortellaro et al., 2006),
instead of the gammaretroviral vector used in the clinical trial. A
long-term comparative approach between these three treatment
options revealed important new information on their efficacy and
established a model for autoimmunity in the context of long-term
PEG-ADA treatment (Sauer et al., 2012a).
The long-term survival of PEG-ADA, HSC-GT, and BMT-
treated mice was comparable between the three groups (60–70%
with respect to wildtype). This outcome was the result of an early
mortality in the BMT and HSC-GT treated groups, while PEG-
ADA treated mice had a less stable long-term survival. As expected
from the fact that PEG-ADA remains in circulation without enter-
ing in cells, ADA activity in PEG-ADA treated mice was exclusively
detectable in the plasma. Reconstitution of enzymatic activity in
RBC, BM, spleen, and thymus from BMT-treated mice was com-
parable to wildtype, while only slightly lower in HSC-GT treated
mice (Sauer et al., 2012a).
Strikingly, ADA−/− mice treated with PEG-ADA developed
multiple autoantibodies and hypothyroidism in contrast to mice
treated with HSC-GT or BMT. Proliferation of various lymphocyte
subpopulations, including B cells and highly abnormal antibody
production affecting all types of antibody subclasses was observed
in PEG-ADA treated mice. Moreover, autoantibodies that reacted
to ADA, platelets, the thyroid, and the gastrointestinal tract were
detected in the sera from PEG-ADA treated mice. Focal atresia with
non-secreting follicles, an increase in apoptotic cells in affected
tissue areas and significantly elevated levels of thyroid-stimulating
hormone (TSH) represent signs of autoimmune hypothyroidism.
The role of autoantibodies against the stomach and intestine devel-
oping in PEG-ADA treated mice, without causing gross patholog-
ical alterations, remained unclear. However, it was hypothesized
that the occurrence of antibody responses to GI tissues not only
interferes with nutrient uptake, but also reflect alterations in
gastrointestinal immunity (Sauer et al., 2012a). The established
mouse model for autoimmunity after PEG-ADA treatment repre-
sents a valuable model for future studies on the in vivo effects of
PEG-ADA on immune cell function and inflammatory responses.
Interestingly, PEG-ADA treated mice produced antibodies to
ADA, platelets, the thyroid, and gastrointestinal tract, but not
other organs such as the pancreas or endocrine glands. The strong
overlap of autoimmune manifestations observed in this model
of autoimmunity in ADA−/− mice with those reported in ADA-
deficient patients suggests that a component of autoimmune sus-
ceptibility may map to the target tissue. In both humans and in
mouse models, single genetic loci have been linked with suscep-
tibility to multiple autoimmune diseases. The genes underlying
such loci, including AIRE, FoxP3, CTLA-4, and PTPN22, are likely
to confer a general predisposition to the failure of immune tol-
erance and development of an auto-aggressive immune response
(Hill et al., 2007). However, other loci are clearly disease specific,
and presumably modify a generalized predisposition to confer
organ/disease specificity. Interestingly, recent studies have impli-
cated ADA polymorphisms in the development of type1 diabetes
and rheumatoid arthritis (Sebastiani et al., 2006; Saccucci et al.,
2009).
ROLE OF ADA METABOLITES IN IMMUNE CELL
DEVELOPMENT AND FUNCTION
Although autoimmunity is frequently observed in certain immun-
odeficiencies, there is accumulating evidence that ADA deficiency
predisposes to this phenomenon not only through general mech-
anisms of immune dysregulation but also through specific alter-
ations caused by the accumulating ADA metabolites. Main fea-
ture of ADA deficiency is the gradual accumulation of adenosine
and 2′-deoxyadenosine nucleosides. In the absence of ADA, these
nucleosides are metabolized differently into AXP or dAXP, respec-
tively, and exert distinct biochemical action (AXP: AMP, ADP,
or ATP; dAXP: dAMP, dADP, or dATP). Several pathophysio-
logical mechanisms have been proposed to describe the role of
ADA substrates in cytotoxicity as well as their immunomodu-
latory properties in patients and in the ADA-deficient mouse
model (Hirschhorn and Candotti, 2006). The major effects of
adenosine, 2′-deoxyadenosine and their nucleotide byproducts are
summarized in Table 1.
CYTOTOXICITY OF 2′-DEOXYADENOSINE AND dATP
Based upon in vivo and in vitro findings, several mechanisms are
believed to account for the block of lymphocyte development in
ADA-SCID (Hirschhorn and Candotti, 2006). The biochemical
hallmarks of ADA deficiency consist of the general belief, that
2′-deoxyadenosine is the primary cause of lymphotoxicity in ADA-
SCID, which exerts its effects at the nucleoside level or after conver-
sion to dATP. Although 2′-deoxyadenosine is a weak substrate for
adenosine kinase and deoxycytidine kinase, in the absence of ADA
these enzymes can phosphorylate 2′-deoxyadenosine. In turn, the
resulting dATP pool expansion may interfere with a number of
critical metabolic pathways.
These ADA substrate accumulations inhibit methyl-transfer
reactions by suicide inactivation of S-adenosylhomocysteine
(SAH) hydrolase (Hershfield et al., 1979). dATP is known to be
a feedback inhibitor of ribonucleotide reductase. Its inhibition
causes an imbalance of deoxynucleotides (dNTP), leading to an
impairment of DNA synthesis, which is critical for the expan-
sion of lymphocytes in response to antigenic challenge (Benveniste
et al., 1995).
ROLE OF ADENOSINE AS ANTI-INFLAMMATORY MEDIATOR
By binding to G-coupled adenosine receptors present on the
surface of target cells, adenosine acts as an extracellular signal
transducer to exert suppressive functions (Sitkovsky et al., 2004).
Physiologically, adenosine-mediated triggering of these receptors
can promote a fine-tuning of the inflammatory responses. In the
context of defective ADA metabolizing enzyme, where the extra-
cellular levels of adenosine are increased, this regulation may be
exaggerated and cause immune dysfunction. This process is mostly
regulated by the aberrant engagement of adenosine 2a receptor
(Adora2a)-mediated signaling.
Functional studies on T cells from ADA-deficient mice and
patients showed an increased susceptibility to apoptosis as well as
altered intra- and extracellular signaling leading to impaired T-cell
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Table 1 | Effects of ADA metabolites on lymphocyte development and function.
ADA metabolite Cell type
Mouse/
human
Mode of action Reference
2′-Deoxyadenosine Lymphocytes Human Inhibition of SAHH activity results in accumulation
of S-adenosylhomocysteine and inhibition of
transmethylation reactions
Hershfield et al. (1979) and Benveniste et al.
(1995)
Fibroblasts Mouse SAHH acts as a physiological modulator of
Fas-mediated cell death
Ratter et al. (1996)
T cells Human Inhibition of T-cell activation by aberrant Adora2a
signaling and PKA hyperactivation
Cassani et al. (2008)
dATP
Lympocytes
and RBC
Human Intracellular ATP depletion Siaw et al. (1980), Simmonds et al. (1982), Koller
et al. (1984), and Simmonds et al. (1984)
T cells Human Inhibition of ribonucleotide reductase causes an
imbalance of dNTPs and an impairment of DNA
synthesis
Waddell and Ullman (1983), Benveniste et al.
(1995)
T cells Human Accumulation of DNA single strand breaks Cohen and Thompson (1986) and
Gangi-Peterson et al. (1999)
T cells Mouse Inhibition of thymocyte development past the
CD4−/CD8− double-negative stage
Van de Wiele et al. (2002) and Van de Wiele
et al. (2006)
B cells Human Nucleotide pool imbalance affects TdT activity
during V(D)J recombination in the bone marrow
Gangi-Peterson et al. (1999)
Adenosine T cells Human Compromised TCR/CD28-driven proliferation and
cytokine production, defective activation of NF-κB
transcriptional events
Cassani et al. (2008)
Resting T cells Human Upregulation of CD152, CTLA-4, normally involved
in the termination of immune responses
Vendetti et al. (2002)
T cells Mouse Decreased TCR-triggered activation and
upregulation of activation markers
Apasov and Sitkovsky (1999), Apasov et al.
(2001)
Activated T cells Mouse Inhibition of IL-2, TNFα, and INFγ secretion Erdmann et al. (2005) and Lappas et al. (2005)
B cells Human Adora2a signaling interferes with BCR- and
TLR-function, inhibition of B-cell activation after
stimulation
Sauer et al. (2012b)
B cells Mouse Profound loss of GC, susceptibility to apoptosis,
defects in B-cell proliferation and activation, block
in Ag-dependent B-cell maturation
Aldrich et al. (2003)
B cells Mouse Increase of intracellular cAMP suppresses the
activation of NF-κB after BCR and TLR-stimulation
Minguet et al. (2005)
Tregs
Mouse/
human
Adora signaling causes alterations in the
CD39/CD73 adenosinergic machinery, upregulation
of FoxP3
Sauer et al. (2012a)
Adaptive Tregs Mouse Adora2a signaling inhibits the generation of
adaptive effector T cells and promotes the
induction of adaptive Tregs, upregulation of FoxP3
Zarek et al. (2008)
ATP T cells Human Purinergic stimulation through P2X receptors
prolongs TCR-initiated activation and IL-2 secretion
Yip et al. (2009)
T cells Mouse Antagonism of P2X blunts TCR-mediated activation
and results in unresponsiveness to subsequent
stimulation
Schenk et al. (2008)
Tregs Mouse Activation of P2X7 inhibits the suppressive
potential and stability of Tregs
Schenk et al. (2011)
Adora2a, adenosine 2a receptor; ATP, adenosine-5′-triphosphate; BCR, B cell receptor; cAMP, 3′,5′-cyclic adenosine monophosphate; dATP, 2′-deoxyadenosine
5′-triphosphate; dNTPs, deoxynucleotides; GC, germinal center; INFγ, interferon gamma; NF-κB, nuclear factor kappa B; P2X/P2X7, purinergic receptors; PKA, cAMP-
dependent protein kinase A; RBC, red blood cells; SAHH, S-adenosylhomocysteine hydrolase; TCR, T-cell receptor; TdT, terminal deoxynucleotidyl transferase; TNFα,
tumor necrosis factor alpha; Tregs, naturally occurring regulatory T cells.
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FIGURE 4 | Immunosuppressive action of adenosine in lymphoid cells.
Upon TCR-antigen-binding and T-cell activation, the translocation of activated
transcription factors and the expression of anti-apoptotic factors supports
their survival, proliferation, and differentiation. The adenosine 2a receptor
(Adora2a) present on T-lymphocytes interacts with coupled G-proteins to
stimulate cAMP formation. The effects of cAMP in T cells are almost entirely
mediated by the cAMP-dependent protein kinase A (PKA). It has been shown
that the inhibitory properties of PKA are mediated via activation of Csk or
inhibition of Raf1. Consistently it has been shown that the severely
compromised effector functions in ADA-deficient T cells associates with an
intrinsically reduced ERK1/2 signaling, a decreased phosphorylation of IκB
and an altered nuclear recruitment of NF-κB. This suggests that the
accumulating adenosine levels in an ADA-deficient environment can directly
antagonize biochemical events arising from TCR engagement.
function (Apasov and Sitkovsky, 1999; Apasov et al., 2001; Cas-
sani et al., 2008). As summarized in Figure 4, the TCR-dependent
activation defect in ADA deficiency is augmented by the immuno-
suppression through extracellular adenosine receptor triggering.
Extracellular adenosine induces increased levels of cAMP in T-
lymphocytes, which inhibits both proximal signaling events after
TCR triggering as well as other downstream effector functions
(Huang et al., 1997; Lappas et al., 2005; Ohta et al., 2009). In accor-
dance with previous data obtained in thymocytes from ADA−/−
mice (Apasov et al., 2001), IκBα phosphorylation after TCR trig-
gering was low or undetectable in ADA-deficient cells (Cassani
et al., 2008). Reduced levels of IκBα phosphorylation and degrada-
tion leads to low levels of NF-κB translocation and transcription of
target genes in the nucleus, thereby contributing to the functional
impairments of ADA-deficient T cells.
Less information is available about the effects exerted by adeno-
sine on B-cell function. Similarly to the alterations in T cells
described above, adenosine receptor ligation in B cells inhibits
downstream responses to antigen receptor engagement like BCR-
induced IκB phosphorylation and the NF-κB pathway after BCR or
TLR4 stimulation (Minguet et al., 2005). Adenosine may thereby
drive BCR-stimulated B cells toward an anergic rather than an
immunogenic response. Recent findings showing defects in BCR
and TLR signaling as well as in tolerance checkpoint control in
human B cells are discussed and illustrated separately in section
“Defects in B-cell tolerance in ADA-SCID.”
Overall, these evidences strongly suggest that rather than
controlling a single pathway downstream of the TCR or BCR,
the immune defects in ADA-deficient lymphocytes may involve
multiple pathways converging toward the defective induction
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of lymphocyte activation. They also illustrate how extracellu-
lar adenosine levels can interfere with the downstream signal-
ing transduction upon activation, thereby exerting its immuno-
suppressive activity on the transcriptional machinery. Because
of cell-specific expression and regulation, aberrant adenosine
receptor-mediated signaling might also contribute to the occur-
rence of autoimmune manifestations observed in some ADA-SCID
patients (Kohn, 1996; Ozsahin et al., 1997).
ROLE OF ATP AND OTHER PURINERGIC RECEPTORS
Stimulation of almost all mammalian cell types leads to the release
of cellular ATP and autocrine feedback through a diverse array of
purinergic receptors (Junger, 2011). ATP binds to two classes of
purinergic P2 receptors in the plasma membrane of eukaryotic
cells: P2X receptors, which are ligand-gated ion channels, and het-
erotrimeric G protein-coupled P2Y receptors (Schenk et al., 2011).
Depending on the types of purinergic receptors that are involved,
autocrine signaling can promote or inhibit immune cell activation
and fine-tune adaptive immune responses (Junger, 2011; Schenk
et al., 2011).
In addition to the autocrine feedback mechanisms that reg-
ulate the function of healthy immune cells, purinergic receptors
allow immune cells to recognize ATP that is released from dam-
aged or stressed host cells. Thus, the purinergic signaling systems
of immune cells serve an important function in the recognition of
danger signals. ATP that is released by stressed cells guides phago-
cytes to inflammatory sites and promotes clearance of damaged
and apoptotic cells (Elliott et al., 2009; Junger, 2011).
To date, little information is available on alterations in the
ATP-induced regulation of immune cells in ADA deficiency. It
is reported that dATP accumulation in the absence of ADA leads
to a cellular depletion of ATP (Siaw et al., 1980; Simmonds et al.,
1982, 1984; Koller et al., 1984). The pool of extracellular ATP on
the other hand might well be augmented in ADA-deficient lym-
phoid organs, due to the increased percentage of cells undergoing
apoptosis. It can therefore be hypothesized that alterations in ATP
concentrations in ADA deficiency also influence T-cell responses
on the level of TCR induced activation and in response to stimuli
from an inflammatory microenvironment.
BREAK OF TOLERANCE AND CONTRIBUTION OF
LYMPHOCYTES TO AUTOIMMUNITY IN ADA DEFICIENCY
Adaptive immunity requires sophisticated regulatory mechanisms
to ensure protection to a variety of pathogenic microbes while
maintaining immune self-tolerance and preventing autoimmunity
(Sakaguchi et al., 2008). The main mechanisms for the induction
and maintenance of a self-tolerant repertoire, which is diverse in
antigen recognition, are central and peripheral tolerance. Central
tolerance is the mechanism able to eliminate newly developing
T cells and B cells that have high affinity to self (Mathis and
Benoist, 2004). Central tolerance is distinct from peripheral tol-
erance in that it occurs while cells are still present in the primary
lymphoid organs, whereas emigrant cells are controlled through
peripheral tolerance mechanisms, after they reach the periphery
(Wardemann and Nussenzweig, 2007; Klein et al., 2009). These
include suppression of autoreactive cells by regulatory T cells and
the generation of hyporesponsiveness (anergy) in lymphocytes,
which encounter antigen in the absence of the co-stimulatory
signals that accompany inflammation (Meffre and Wardemann,
2008).
Numerous mechanisms have been proposed to explain the
break of tolerance and development of autoimmune manifes-
tations, such as defective negative selection of autoreactive T-
lymphocytes in the thymus, alterations in the number and/or
function of regulatory T cells, defects of the central and peripheral
B-cell tolerance checkpoints, impaired apoptosis of autoreactive
lymphocytes, break of tolerance due to increased or decreased
clearance of apoptotic cells and pathogens, or increased homeosta-
tic lymphoid proliferation and cytokine secretion associated with
lymphopenia (Carneiro-Sampaio and Coutinho, 2007; Westerberg
et al., 2008; Notarangelo, 2009; Meffre, 2012).
T-CELL TOLERANCE
Central T-cell tolerance mechanisms are based on the elimination
or negative selection of the majority of T cells recognizing self
with high affinity for negative selection in the thymus. Nonethe-
less thymic selection is not a tight process and T cells expressing
low-avidity TCR on their cell surface are frequently released in the
periphery, where they are potentially dangerous to the host as they
can be effectively recruited into an autoimmune response (Parish
and Heath, 2008).
A major cause of tolerance breakdown is associated with lym-
phopenia (Daikeler and Tyndall, 2007). This typical state of pri-
mary immunodeficiencies may contribute to the induction of
spontaneous homeostatic proliferation of residual T cells allowing
peripheral expansion of autoreactive cells with a skewed reper-
toire. Particularly, after conditioning or transplantation these cells
may persist, since insufficient thymic reconstitution may affect the
control of self-reactivity due to defective negative selection in the
thymus and/or reduced regulatory T-cell development and func-
tion (Hauri-Hohl et al., 2007). In the case of ADA deficiency, it has
been hypothesized that the structure and functions of the thymic
microenvironment might be altered, either directly, by toxicity
of purine metabolites, or indirectly, by failure of T cells arrested
in their development to deliver supportive signals to the thymic
stroma (Apasov et al., 2001).
Peripheral tolerance depends on the balance between immune
responses to invading pathogens and immune tolerance to self-
antigens. In the context of tissue damage and frequently occurring
infections in primary immunodeficient patients, apoptotic cells
represent a major source of autoantigen. Since apoptosis plays a
major role in the deletion of autoreactive lymphocytes and the
removal of virus-infected cells, defects in cell death have been
implicated in the development of autoimmune diseases and per-
sistent viral infection (Utz et al., 2000). The release of self-antigen
into the intracellular space and their presentation mediated by
dendritic cells or other antigen-presenting cells may prime naive
autoreactive T cells, which were not eliminated by depletion or
anergy (Waldner et al., 2004). Several mechanisms exist, includ-
ing a spectrum of CD4+ regulatory T cells (Tregs), to suppress
self-reactive T cells that escape thymic clonal deletion and atten-
uate anti-pathogen effector mechanisms from inducing immune
pathology (Piccirillo and Thornton, 2004). There is ample evi-
dence that Tregs actively mediate suppression to control immune
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responses to self- and non-self-antigens and the onset of autoim-
munity (Bach,2003; Sakaguchi,2005). Lessons from other primary
immunodeficiencies have provided unequivocal evidence for the
essential role of Tregs in suppressing autoreactive T cells in the
periphery (Westerberg et al., 2008). Rising of autoimmunity may
not only be linked to a reduction in Treg numbers but also to atten-
uation of their suppressive activity (Sakaguchi et al., 2008). While
this is principally mediated by cell–cell contact, recent findings
revealed additional mechanisms of Treg-mediated suppression,
including secretion of immunosuppressive cytokines, functional
modification or killing of APC, and metabolic disruption (Vig-
nali et al., 2008). Moreover, extracellular adenosine produced by
Tregs, has been identified as one of the mechanisms mediating
their suppressive activity (Sitkovsky et al., 2008; Mandapathil et al.,
2010). Treg cells possess a unique biochemical signature amongst
T cells in that they generate and sustain high adenosine con-
centrations. Since Tregs primarily mediate peripheral control of
autoreactive T cells, it is conceivable that this compartment might
be specifically affected in ADA-SCID (see also Defective Regulatory
T Cell Function in ADA Deficiency). Consequently the autoim-
mune manifestations associated with ADA deficiency might be
the result of an altered purine metabolism interfering with normal
regulatory T-cell function (Sauer et al., 2012a).
B-CELL TOLERANCE
A variety of mechanisms ranging from clonal deletion to func-
tional inactivation by anergy of autoreactive B cells serve to shape
the peripheral B-cell repertoire. Nevertheless, dysregulation of B
cell development and autoantibody production is a characteris-
tic of most autoimmune diseases including rheumatoid arthri-
tis, systemic lupus erythematosus, and type 1 diabetes, but also
immunodeficiencies such as CVID, Wiskott–Aldrich Syndrome,
and X-linked agammaglobulinemia (Park et al., 2005; Cuss et al.,
2006; Westerberg et al., 2008). In ADA deficiency, some of the
observed immune dysregulation were hypothesized to be associ-
ated with a more restricted B-cell repertoire due to abnormalities
in central B-cell generation or to a dysregulated expansion of these
cells in the periphery.
Autoantibodies appear in the serum many years before the
onset of clinical disease suggesting an early break in B-cell
tolerance (Wardemann et al., 2003). Some of B-cell mediated
autoimmune diseases, such as myasthenia gravis (MG), idiopathic
autoimmune thrombocytopenic purpura (AITP), and Graves’ dis-
ease are characterized by auto-Abs production that destroy target
tissues (Barsalou et al., 2011; Cunningham-Rundles, 2011). A
remarkably high proportion of autoantibodies associated with sys-
temic autoimmune diseases binds DNA, RNA, or macromolecular
complexes that contain DNA or RNA. It has been hypothesized,
that under certain circumstances these intracellular autoantigens
become visible to the immune system when they accumulate dur-
ing apoptosis. In fact the impaired clearance of apoptotic cell
debris and dsDNA by macrophages might induce TLR signal-
ing and differentiation of autoreactive B cells (Gaipl et al., 2006).
Response to nucleic acid-containing immunecomplexes relies on
the coengagement of endosomal members of the TLR family, TLR9
and TLR7 (Marshak-Rothstein, 2006). Therefore, self-antigens
that can effectively engage both the BCR and either TLR7 or TLR9
might stimulate autoreactive B cells that are normally quiescent,
through inherent adjuvant activity and trigger the development of
systemic autoimmune disease (Marshak-Rothstein, 2006). In ADA
deficiency, the metabolic basis underlying immune cell deficiency
is the cytotoxic effect impact of the ADA substrates deoxyadeno-
sine and dATP, leading to apoptosis of lymphocytes. It is therefore
conceivable that developing B lymphocytes in affected lymphoid
organs encounter massive amounts of nucleic acid. Nucleic acid-
sensing TLRs might therefore represent Achilles’heel in susceptible
ADA-deficient patients by which relative tolerance for nucleic acid-
containing antigens is breached and autoimmunity occurs (Kono
et al., 2009).
NEW INSIGHTS INTO IMMUNE CELL DYSFUNCTION AND
ONSET OF AUTOIMMUNITY IN ADA DEFICIENCY
Recent in-depth studies have revealed specific defects in ADA
deficiency that may contribute to the onset of autoimmunity in
these patients. Herein we discuss alterations in the adenosiner-
gic machinery of ADA-deficient regulatory T cells and in B-cell
tolerance in the absence of functional ADA.
DEFECTIVE REGULATORY T-CELL FUNCTION IN ADA DEFICIENCY
Although autoimmune manifestations are frequent findings
in ADA-deficient patients with milder forms or in patients
under PEG-ADA, mechanisms causing the loss of peripheral
tolerance and onset of autoimmunity have remained elusive.
CD4+CD25+FoxP3+ Tregs actively suppress pathological and
physiological immune responses in order to maintain periph-
eral immune self-tolerance and prevent autoimmunity (Sakaguchi
et al., 2008; Sitkovsky et al., 2008). Extracellular adenosine pro-
duced by Tregs has been described as one of the mechanisms
mediating their suppressive activity (Figure 5A). Concordant
expression of the ectoenzymes CD39 and CD73 has been reported
both for murine and human Tregs (Borsellino et al., 2007; Deaglio
et al., 2007; Mandapathil et al., 2010). The CD39 ectoenzyme pro-
duces AMP from ATP or ADP, which is subsequently converted
into extracellular adenosine by the CD73 ectoenzyme (Hasko et al.,
2008). Treg function requires the coordinated expression of the
Adora2a on activated T effector cells to enable adenosine-mediated
immunosuppression (Sitkovsky et al., 2008). Moreover, Tregs have
been shown to express low levels of ADA, whereas T effector cells
are enriched in ADA but express low levels of CD39 and CD73
(Mandapathil et al., 2010; Sauer et al., 2012a). This molecular pro-
file of Tregs (CD39+CD73+ADAlow) has functional importance,
as it not only confers Tregs the capability to produce extracellular
adenosine but also to sustain relatively high concentrations due to
low ADA expression (Mandapathil et al., 2010).
Figure 5B summarizes recently described defects and func-
tional alterations of the adenosinergic pathway in Tregs from ADA-
deficient mice and patients (Sauer et al., 2012a). ADA−/− Tregs
showed significantly higher expression of CD39, while expressing
significantly less CD73. ADA−/− Tregs are sensitive to extra-
cellular adenosine concentrations and the expression of CD73
is regulated by this metabolite. With adenosine accumulating in
ADA−/− mice, possibly to avoid a further increase of extracellu-
lar concentrations, CD73 is reduced and ADA−/− Tregs display a
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FIGURE 5 | Loss of regulatoryT-cell function in ADA-SCID. (A) By
concomitant expression of CD39 and CD73, Tregs have the enzymatic
machinery to generate and maintain high levels of extracellular adenosine.
Contrarily to T effector cells, Tregs express low levels of ADA and CD26.
Extracellular ATP or ADP is converted by the ectonucleotidase CD39 into
AMP, which is further converted into adenosine by the CD73 ectoenzyme.
The produced adenosine binds to the Adora2A receptor expressed on
activated effector T cells, which are enriched in ADA and the surface-bound
glycoprotein CD26. The coordinated expression of CD39 and CD73 on Tregs
and Adora2a on T effector cells enables adenosine-mediated
immunosuppression. (B) In the absence of ADA, deficient Tregs express
high levels of CD39, increasing their capacity for ATP hydrolysis, but
reduced levels of CD73 on their surface. Although both CD39 and CD73 are
rate limiting for extracellular adenosine generation, CD73 is the last
component of the ectoenzymatic chain. With accumulating adenosine
levels, possibly to avoid a further increase of extracellular concentrations,
CD73 is reduced and ADA−/−Tregs display a decreased suppressive
activity toward T effector cells. Nevertheless no apparent autoimmune
manifestations can be observed at onset, likely due to the severely reduced
effector T- and B-cell populations. Moreover, the accumulating extracellular
adenosine is likely to maintain an anti-inflammatory environment in these
mice. (C) After PEG-ADA treatment, the adenosinergic machinery of CD39
and CD73 are upregulated, indicating an increased requirement for ATP
hydrolysis and enhanced adenosine production. Despite the initial rescue of
suppressive activity by upregulation of CD73 for elevated adenosine
production, long-term PEG-ADA treatment interferes with Treg function by
augmenting adenosine turnover. PEG-ADA present in the extracellular space
eliminates adenosine produced by the ectoenzymatic chain and hinders
adenosine-mediated suppression by interfering between adenosine and
Adora2a expressed on T effector cells.
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decreased suppressive activity toward T effector cells. The under-
lying mechanism accounting for increased CD39 expression in
ADA−/− Tregs remains to be elucidated. However, intracellular
cAMP levels, which are elevated in the absence of ADA, have been
reported to increase CD39 expression (Liao et al., 2010).
In order to dissect the cellular mechanisms leading to loss
of peripheral tolerance, ADA−/− mice were studied after treat-
ment with PEG-ADA, HSC-GT, and BMT. Although short-term
PEG-ADA treatment initially rescued Treg-mediated suppression
in comparison to untreated ADA−/− mice, their functional-
ity became exhausted by long-term PEG-ADA treatment. Tregs
from PEG-ADA treated animals maintained increased expres-
sion of CD39 and upregulated CD73 expression in comparison
to age-matched wildtype controls. Consistently, CD39 activity
measured by ATP consumption and AMP formation, as well
as adenosine production by CD73 were significantly increased
in comparison with wildtype Tregs. These results were con-
firmed in a cohort of patients including 7 PEG-ADA treated
and 11 retroviral HSC-GT treated patients. The percentage
of CD4+CD25+FOXP3+CD127−/low Tregs was significantly
reduced in PEG-ADA treated patients and their expression of
CD39 and CD73 ectonucleotidase were significantly increased.
Unlike Tregs from HSC-GT treated patients and HD, Tregs iso-
lated from PEG-ADA treated patients were unable to suppress the
proliferation of effector cells (Sauer et al., 2012a).
The obtained results revealed an elevated adenosine catab-
olism in the presence of PEG-ADA, characterized by alter-
ations in the adenosinergic machinery producing high levels of
adenosine and a significantly increased turnover by the enzy-
matic activity of PEG-ADA. Upregulation of CD73 in treated
ADA−/− mice and patients can therefore be interpreted as a
compensatory mechanism representing a higher requirement for
ATP/ADP to adenosine conversion in the presence of extracel-
lular PEG-ADA. Despite the initial rescue of suppressive activ-
ity by upregulation of CD73 for elevated adenosine production,
long-term PEG-ADA treatment interfered with Treg function by
augmenting adenosine turnover. These findings fit the hypoth-
esis that PEG-ADA present in the extracellular space eliminates
adenosine produced by this ectoenzymatic chain and hinders
adenosine-mediated suppression by interfering between adeno-
sine and Adora2a expressed on T effector cells (Sauer et al., 2012a;
Figure 5C).
DEFECTS IN B-CELL TOLERANCE IN ADA-SCID
Although PEG-ADA induces metabolic detoxification, BMT and
HSC-GT provide superior restoration of purine metabolism
and immune functions. However, it had remained unclear how
patient’s B cells contribute to autoimmune complications and if
B-cell tolerance is established properly in ADA-deficient patients
before and after treatment.
Random V(D)J recombination produces large numbers of anti-
bodies displaying self-reactive specificities and during normal
B-cell development the majority of these antibodies are removed
at two distinct checkpoints in the bone marrow and periphery
(Wardemann et al., 2003). Large numbers of self-reactive antibod-
ies are removed from the B cell repertoire during the immature
B cell stage in the bone marrow, where BCR-mediated selection
plays a crucial role in controlling B-cell survival based on exces-
sively strong or weak BCR signals that identify autoreactive or
functionally unfit B cells (Goodnow, 1996; Nemazee et al., 2000;
Cancro, 2009; Figure 6). Alterations of BCR signaling thresh-
olds result in a defective central B-cell tolerance checkpoint and
interfere with the removal of developing autoreactive B cells in
humans (Ng et al., 2004; Menard et al., 2011). In addition to their
BCRs, B cells also express TLRs that were originally described to
bind microbial components but that are also able to recognize
self-antigens (Marshak-Rothstein, 2006) and are involved in the
removal of developing anti-nuclear antibody (ANA)-expressing
B cells (Isnardi et al., 2008). Both BCR- and TLR-mediated B-cell
responses have been reported to be modulated by adenosine recep-
tor signaling and intracellular cyclic adenosine monophospate
(cAMP), which are increased in ADA deficiency (Apasov et al.,
2001; Hershfield, 2005; Minguet et al., 2005; Power Coombs et al.,
2011).
B-cell tolerance checkpoints in ADA-SCID patients were
assessed by cloning antibodies expressed by single B cells before
and after successful HSC-GT (Sauer et al., 2012b). New emi-
grant/transitional and mature naïve B cells from ADA-deficient
patients before HSC-GT contained high frequencies of autore-
active and ANA-expressing clones compared to healthy donors,
revealing defective central and peripheral B-cell tolerance check-
points in the absence of functional ADA.
The receptor candidates for the removal of ANA-expressing
clones are nucleic acid-sensing endosomal members of the TLR
family, TLR7 and TLR9 (Marshak-Rothstein, 2006), thereby sug-
gesting that ADA impinges not only on BCR but more importantly
TLR signaling. A similar mechanism has also been hypothesized
to contribute to B-cell dysfunctions, defective B-cell proliferation,
and activation observed in ADA-deficient mice (Aldrich et al.,
2003; Hershfield, 2005). The accumulating adenosine blocks NF-
κB activation in murine B cells stimulated through BCRs or TLR4
by LPS (Minguet et al., 2005; Power Coombs et al., 2011). In line
with this hypothesis, we found that stimulation through TLR7
and TLR9 were significantly dependent on proper ADA enzymatic
activity and adenosine receptor engagement, further underlin-
ing the inability of these receptors to function in the absence of
functional ADA (Figure 6).
Strikingly, ADA-deficient patients treated with HSC-GT dis-
played quasi-normal early B-cell tolerance checkpoints as evi-
denced by restored efficient removal of developing autoreactive
and anti-nuclear B cells. Hence, ADA plays an essential role in the
establishment of early B-cell tolerance and the removal of devel-
oping autoreactive B cells in humans (Luning Prak, 2012; Sauer
et al., 2012b).
CONCLUDING REMARKS ON THE OCCURRENCE OF
AUTOIMMUNITY AFTER ADA-SCID TREATMENT
In summary, the available literature provides supporting evidence
for a predisposition to autoimmunity in ADA deficiency. Alter-
ations in both central and peripheral tolerance in T- and B-cells
have been described to contribute to the pathogenesis of autoim-
munity. Moreover, it is becoming increasingly clear that tolerance
mechanisms and immune responses are specifically altered by the
lack of ADA and the accumulation of its substrates.
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FIGURE 6 | Development of ANA-expressing B-cell clones in ADA
deficiency. (A) During B-cell development in the bone marrow, BCR signals
provide a cell-intrinsic measure for negative or positive selection. By
excessively weak or strong BCR signals, two thresholds identify
functionally unfit or autoreactive B-cell clones. B cells that fail to rearrange
and signal through their BCR die of neglect. Negative selection against
autoreactive BCR specificities occurs following high avidity BCR
interactions with antigen. While positive selection of B-cells requires
persistent intermediate BCR signaling in both developing and mature
B-cells. (B) Upon antigen-binding the BCR is internalized and transported to
the cytoplasmic compartments containing Toll-like receptor 9 (TLR9) or
TLR7. Physiological engagement of immunoreceptors leads to the
phosphorylation and proteasomal degradation of IκB, thereby releasing
NF-κB into the cytoplasm. Subsequently, NF-κB translocates to the nucleus
and initiates the transcription of NF-κB target genes required for immune
cell development and function. During the bone marrow differentiation of B
cells, a major source of autoantigen is developing lymphocytes, which
undergo apoptosis. Autoantigens are released in the extracellular space
and form immune complexes. Binding of nucleic acid-containing immune
complexes to an autoreactive BCR produces a strong activation signal
through simultaneous activation of TLRs and leads to the depletion or
receptor editing of the B cell. It can be hypothesized that in ADA deficiency
this negative selection is dampened by adenosine present in the
extracellular place and engagement of the Adora2a. Activation of Adora2a
elevates intracellular cAMP through activation of adenylyl cyclase. In turn,
cAMP activates PKA that blocks the BCR-induced phosphorylation of IκB to
inhibit immunoreceptor-mediated NF-κB activation in the cytoplasm. The
strong depletion signal coming from BCR and TLR coengagement is
thereby lowered and ADA-deficient B cells carrying an autoreactive BCR
egress into the periphery.
Particularly, the impact of accumulating adenosine as anti-
inflammatory mediator has to be underlined in ADA deficiency.
The ligation of Adora2a receptors leads to an increase in cAMP lev-
els, which in cooperation with PKA induces immunosuppression,
attenuation of proximal signaling events after TCR and BCR trig-
gering, and inhibition of downstream effector functions (Skalhegg
et al., 1992; Huang et al., 1997; Lappas et al., 2005; Cassani et al.,
2008; Sauer et al., 2012b). It can further be hypothesized that
dampening of TCR- and BCR-downstream signaling interferes
with the depletion signals during negative selection in central tol-
erance, thereby allowing the survival of autoreactive cells in ADA
deficiency. In addition to its effects on T- and B-cells, adenosine
is an important regulator, physiologically involved in inhibiting a
variety of activated immune cells and in protecting tissues from
acute inflammatory damage (Panther et al., 2003; Sitkovsky et al.,
2004). Indeed we showed that Tregs require a balanced adenosine
metabolism to exert their suppressive activity, since excessively
high adenosine concentrations, or excessive conversion of extra-
cellularly produced adenosine by PEG-ADA interferes with their
suppressive function (Luning Prak, 2012; Sauer et al., 2012a).
The precise role of PEG-ADA alongside other treatment
options is still undetermined, but it certainly allows rapid detox-
ification and stabilization of patients awaiting more definitive
treatment (Booth and Gaspar, 2009). With a progressive loss of
lymphocyte functions, the occurrence of neutralizing anti-ADA
antibodies and autoimmune manifestations, long-term immuno-
logical reconstitution in PEG-ADA patients is often incomplete. It
has been hypothesized that partial ADA correction resulting in low
enzymatic activity may mimic late-onset patients, which typically
display a higher prevalence of autoimmune manifestations (Ochs
et al., 1992; Ozsahin et al., 1997; Luning Prak, 2012). Indeed, recent
data underlined the importance of intracellular ADA expression
Frontiers in Immunology | Primary Immunodeficiencies August 2012 | Volume 3 | Article 265 | 14
Sauer et al. Autoimmunity in ADA-SCID
and superior efficacy of gene therapy over PEG-ADA treatment for
the development of functional T- and B-cell tolerance, including
Tregs (Sauer et al., 2012a,b).
Both BMT and HSC-GT provide efficient reconstitution of
the immune system through endogenous enzymatic ADA activ-
ity. BMT from an HLA-identical sibling donor remains the
treatment of choice, while transplants from alternative donors
are associated with high morbidity and mortality. The occur-
rence of mixed chimerism in transplanted patients with other
primary immunodeficiencies is associated with a higher inci-
dence of autoimmune manifestations (Moratto et al., 2011) and
might well play a role also in ADA deficiency (Cancrini et al.,
2010). Moreover, transplantation-induced lymphopenia is a pos-
sible cause for the homeostatic expansion of autoreactive T-
and/or B-cells with subsequent loss of self-tolerance (Daikeler
and Tyndall, 2007). Phenomena of immune dysregulation as
occurring in the context of pre-transplant conditioning and
BMT might further trigger the onset of autoimmunity (Etzioni,
2003).
In accordance with the current guidelines of the European
group for Blood and Marrow Transplantation (EBMT) and given
the long-term experience in gene therapy (Aiuti et al., 2009), this
treatment can now be considered for all ADA-SCID patients lack-
ing an HLA-identical sibling donor (Gaspar et al., 2009). After
HSC-GT, high levels (50–90% on average) of gene correction were
detected in T- and B- and NK-cells (Aiuti et al., 2009), leading
to an efficient systemic detoxification and recovery of immune
cell functions. However, as suggested by the cloning of single
B-cell receptors, non-gene corrected cells may carry autoreactive
specificities (Sauer et al., 2012b). It can be hypothesized that the
co-existence of non-corrected autoreactive T- or B-cells and the
restored functional T cell help could allow the development of
autoimmune manifestations in ADA-SCID patients after HSC-
GT (Aiuti et al., 2009). Modification of preparatory regimen or
increased gene transfer efficiency by more robust approaches such
as lentiviral vectors may further improve HSC-GT outcome for
ADA deficiency (Mortellaro et al., 2006).
Adenosine deaminase-SCID remains a challenging condition
to treat (Gaspar et al., 2009). With large-scale outcome studies still
lacking, the choice between lifelong PEG-ADA, unrelated BMT
and HSC-GT is currently based on the risk/benefit ratio, the avail-
ability, and costs of the three different treatment options (Gaspar
et al., 2009). Due to the rarity of the disease and the small cohort
numbers, accurate survey and long-term follow-up will be essen-
tial to determine the outcome following different treatments and
their efficacy in restoring immune tolerance.
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